PDCD1 and nasopharyngeal carcinoma: For randomized controlled trial (RCT) study, ORR [OR = 1.11, 95% CI (.49, 2.52); <i>p</i> = .812], OS [1-year OR = 1.26, 95% CI (.76, 2.08); <i>p</i> = .367], [2-year OR = 1.04, 95% CI (.39, 2.71); <i>p</i> = .928] in patients with metastatic/recurrent NPC were consistent with PD-1 inhibitor therapy and conventional chemotherapy.